



ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA
DIPARTIMENTO DI
SCIENZE MEDICHE E CHIRURGICHE

POLICLINICO DI
SANT'ORSOLA

SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Azienda Ospedaliero - Universitaria di Bologna

Aggressive Lymphoma Workshop

Bologna, Royal Hotel Carlton
May 8-9, 2023

President: **Pier Luigi Zinzani**

AUSPICES

Alma Mater Studiorum - Università degli Studi di Bologna

Azienda Ospedaliero-Universitaria di Bologna

Regione Emilia-Romagna

AIL - Associazione Italiana contro le leucemie, linfomi e mieloma - sezione di Bologna

SIE - Società Italiana di Ematologia

Faculty



Jeremy S.	Abramson	Boston, USA
Stephen M.	Ansell	Rochester, USA
Elizabeth L.	Budde	Duarte, USA
Carmelo	Carlo-Stella	Rozzano - MI, Italy
Bjoern	Chapuy	Berlin, Germany
Julio C.	Chavez	Tampa, USA
Bruce D.	Cheson	Washington, USA
Paolo	Corradini	Milan, Italy
Kate	Cwynarski	London, UK
Riccardo	Dalla Favera	New York, USA
Peter K.	Dreger	Heidelberg, Germany
Johannes A.	Duell	Wuerzburg, Germany
Andrés J.M.	Ferreri	Milan, Italy
Martin	Hutchings	Copenhagen, Denmark
Elaine S.	Jaffe	Bethesda, USA
Jaya	Kala	Houston, USA
Wonseog	Kim	Seoul, Korea
Frederick	Locke	Tampa, USA
Armando	Lopez-Guillermo	Barcelona, Spain
Pieterella J.	Lugtenburg	Rotterdam, The Netherlands
Maurizio	Martelli	Rome, Italy
Ari M.	Melnick	New York, USA
Jean-Marie	Michot	Villejuif, France
Javier L.	Munoz	Phoenix, USA
Grzegorz S.	Nowakowski	Rochester, USA
Stefano A.	Pileri	Bologna, Italy
Antonio	Pinto	Naples, Italy
Craig A.	Portell	Charlottesville, USA
Umberto	Ricardi	Turin, Italy
Luigi	Rigacci	Rome, Italy
Mark	Roschewski	Bethesda, USA
Davide	Rossi	Bellinzona, Switzerland
Elena	Sabattini	Bologna, Italy
Kerry J.	Savage	Vancouver, Canada
Roland	Schmitz	Giessen, Germany
Stephen J.	Schuster	Philadelphia, USA
David W.	Scott	Vancouver, Canada
Laurie	Sehn	Vancouver, Canada
Michele	Spina	Aviano-PN, Italy
Maarten H.	Vermeer	Leiden, The Netherlands
Umberto	Vitolo	Candiolo-TO, Italy
Michael	Wang	Houston, USA
Pier Luigi	Zinzani	Bologna, Italy

Aggressive
Lymphoma
Workshop

09.00 am Welcoming remarks and introduction P.L. Zinzani

SESSION I: Histopathology, biology and... other

Chairmen: *S.A. Pileri, E. Sabbatini*

09.10 am Histology *E.S. Jaffe*
 09.30 am Epigenetic evolution in lymphoma *A.M. Melnick*
 09.50 am Genetic landscape of DLBCL *R. Dalla Favera*
 10.10 am Mechanism-based therapy of DLBCL *M. Roschewski*
 10.30 am Use of circulating tumor DNA to genotype aggressive lymphoma *D. Rossi*

SESSION II: Precision medicine in DLBCL

Chairmen: *S.M. Ansell, B. Chapuy*

11.00 am Genomic classification of DLBCL: implications for precision medicine *R. Schmitz*
 11.20 am Practical considerations for using genome sequencing data for patient selection *D.W. Scott*
 11.40 am Molecular predictors of response *B. Chapuy*
 12.00 pm Precision medicine in the era of combination therapy *S.M. Ansell*

SESSION III: Specific therapeutical approaches in DLBCL

Chairman: *M. Spina*

12.30 pm Role of radiotherapy *U. Ricardi*
 12.45 pm Allotransplant: is there yet a role? *P.K. Dreger*
 01.00 pm CNS prophylaxis *K. Cwynarski*
 01.15 pm Glucarpidase and high-dose methotrexate *J. Kala*
 01.45 pm **Lunch**

SESSION IV: Update on frontline treatments and beyond

Chairmen: *G.S. Nowakowski, A. Pinto*

02.45 pm How to treat early stage DLBCL *A. Lopez-Guillermo*
 03.05 pm Advanced stage: moving beyond R-CHOP *G.S. Nowakowski*
 03.25 pm Focus on high-risk patients *J.C. Chavez*
 03.45 pm How to treat elderly patients *P.J. Lugtenburg*
 04.05 pm Is it time to explore the concept of "Replace R-CHOP"? *B.D. Cheson*

SESSION V: Bispecifics

Chairmen: *C. Carlo-Stella, M. Hutchings*

04.30 pm Epcoritamab *P.J. Lugtenburg*
 04.50 pm Glofitamab *M. Hutchings*
 05.10 pm Odronektamab *W. Kim*
 05.30 pm Mosunetuzumab *E.L. Budde*

Aggressive
 Lymphoma
 Workshop

SESSION VI: CAR T-Cell in DLBCL and MCL

Chairmen: *P. Corradini, P.L. Zinzani*

- 08.45 am **Third Line DLBCL:**
- Juliet study and RWD
 - Transcend study and RWD
 - ZUMA-1 study and RWD

S.J. Schuster
J.S. Abramson
F. Locke

- 09.50 am **Second Line DLBCL**
- ZUMA-7 study
 - TRANSFORM study

F. Locke
J.S. Abramson

10.30 am **Round table**

- 11.15 am **Third line MCL**
- ZUMA-2 and RWD

M. Wang

SESSION VII: New drugs in DLBCL (I)

Chairmen: *B.D. Cheson, U. Vitolo*

- 11.45 am Polatuzumab vedotin
 12.05 pm Tafasitamab + Lenalidomide
 12.25 pm Loncastuximab tesirine
 12.45 pm Zilovertamab vedotin

L. Sehn
J.A. Duell
C. Carlo-Stella
M. Wang

01.15 pm **Lunch**

SESSION VIII: New drugs in DLBCL (II)

Chairmen: *S.M. Ansell, L. Rigacci*

- 02.15 pm CC-99282
 02.30 pm Iberdomide
 02.45 pm CDK9 inhibitor
 03.00 pm CD47

J.M. Michot
J.L. Munoz
C.A. Portell
S.M. Ansell

SESSION IX: Other aggressive entities and situations

Chairmen: *M. Martelli, K.J. Savage*

- 03.30 pm Cutaneous T-cell lymphoma
 03.50 pm Burkitt lymphoma
 04.10 pm Primary mediastinal lymphoma
 04.30 pm Mantle cell lymphoma
 04.50 pm Peripheral T-cell lymphoma
 05.10 pm Primary CNS lymphoma

M.H. Vermeer
J.S. Abramson
P.L. Zinzani
M. Wang
K.J. Savage
A.J.M. Ferreri

05.30 pm **Arrivederci!**

P.L. Zinzani

Aggressive
 Lymphoma
 Workshop

With an unrestricted educational grant of:



Meeting venue

Royal Hotel Carlton
Via Montebello, 8 - 40121 Bologna, Italy
Phone +39 051 249361 - Fax +39 051 249724
www.royalhotelcarltonbologna.com

Registration and Fees

Registration is available at www.ercongressi.it - section "I nostri congressi/anno 2023"

Registration fee Euro 250,00 (Italian VAT included)

The registration fee includes: conference kit, participation in the scientific sessions, attendance certificate, coffee break, lunch, slides of the meeting.

Badge and certificate of attendance

All registered participants, speakers and sponsors will be given a badge which they must wear to be admitted to the scientific sessions. A certificate will be given to all participants at the end of the meeting.

Italian CME credits

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi SRL: ID 828-370405.
- No. 7 CME credits for Physicians (disciplines: Hematology, Oncology, Radiotherapy, Pathological Anatomy, Clinical Pathology) and Biologists.
- Educational objective: "linee guida-protocolli-procedure".

European CME credits

The program of the "Aggressive Lymphoma Workshop" has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. 10 CME credits for Physicians and Biologists. To request credits, please fill out the form and return it to the registration desk at the end of the meeting. We remind you that it is necessary to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: <http://ebah.org> even on site.

Changes

Parts of the program may be changed without notice.

Scientific Secretariat

Pier Luigi Zinzani
Istituto di Ematologia
"Lorenzo e Ariosto Seràgnoli"
Via Massarenti, 9 - 40138 Bologna, Italy

Organizing Secretariat

Studio E.R. Congressi
Via De' Poeti, 1/7 - 40124 Bologna, Italy
Phone +39 051 4210559
E-mail: ercongressi@ercongressi.it
www.ercongressi.it